

Model / Variable	Beta	95% CI		P value
		Lower	Upper	
Main model				
b/tsDMARD use	-0.00544	-0.01177	0.00090	0.091
DAS28-ESR	0.00581	0.00138	0.01025	0.011
Model 1: Main model + any anti-osteoporosis medication use				
b/tsDMARD use	-0.00544	-0.01182	0.00095	0.094
DAS28-ESR	0.00582	0.00134	0.01029	0.012
Any anti-osteoporosis medication use	-0.00008	-0.00605	0.00588	0.978
Model 2: Main model + cumulative glucocorticoid exposure				
b/tsDMARD use	-0.00487	-0.01135	0.00161	0.138
DAS28-ESR	0.00657	0.00158	0.01157	0.011
Cumulative glucocorticoid exposure	0.00012	-0.00024	0.00047	0.512
Model 3: Main model + any anti-osteoporosis medication use + cumulative glucocorticoid exposure				
b/tsDMARD use	-0.00486	-0.01139	0.00167	0.142
DAS28-ESR	0.00668	0.00159	0.01177	0.011
Any anti-osteoporosis medication use	-0.00088	-0.0072	0.00545	0.783
Cumulative glucocorticoid exposure	0.00013	-0.00024	0.00050	0.483

Supplementary Table S2 Sensitivity analyses for factors associated with serum pentosidine levels. The main model included b/tsDMARD use, age, DAS28-CRP, and DAS28-ESR. Model 1 additionally included any anti-osteoporosis medication use. Model 2 additionally included cumulative glucocorticoid exposure. Model 3 additionally included both any anti-osteoporosis medication use and cumulative glucocorticoid exposure. Any anti-osteoporosis medication use included bisphosphonates, SERMs, active vitamin D analogues, denosumab, PTH analogues, and romosozumab.

Abbreviations: CI, confidence interval; b/tsDMARD, biological or targeted synthetic disease-modifying antirheumatic drug; DAS28, Disease Activity Score in 28 joints; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.